New Blood Cancer Vaccine Reduces Death Risk By 41%
A new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical … Read More The post New Blood Cancer Vaccine Reduces Death Risk By 41% appeared first on ProPakistani .
A groundbreaking vaccine aimed at combating aggressive blood cancer has demonstrated impressive results in a major clinical trial, cutting the mortality risk for specific leukemia patients by 41%, according to recent findings. The vaccine, called galinpepimut-S (GPS), was developed at Memorial Sloan Kettering Cancer Center and evaluated by Sellas Life Sciences in a Phase 3 study involving 126 individuals diagnosed with acute myeloid leukemia (AML).
Results unveiled that patients who received the vaccine experienced a median survival of 24 months, in contrast to 14.7 months for those receiving alternative treatment options. AML, a malignant form of blood cancer, affects around 20,000 individuals each year in the United States. While chemotherapy can temporarily put the disease into remission, it often returns, posing challenges for long-term treatment.
The trial specifically targeted patients whose leukemia had recurred following prior treatment but who had regained remission and were unsuitable for bone marrow transplants. Distinct from vaccines meant to prevent diseases, GPS operates by aiding the immune system to recognize and eliminate residual leukemia cells post-chemotherapy, potentially lowering the likelihood of the cancer's recurrence.
The vaccine employs peptides, fragments of proteins, to incite an immune response against cancer cells, and can be manufactured as a standard treatment without necessitating a distinct formulation for each patient. Sellas disclosed that the vaccine was generally well-tolerated, with the most common side effect being reactions at the injection site.
The company intends to unveil a comprehensive analysis of the trial data at a future medical conference and petition approval from the US Food and Drug Administration (FDA), with a submission expected in the first half of 2027.
Written by urgent.news from ProPakistani's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.